. NKT cells express an invariant TCRα chain rearrangement: Vα14Jα18 in mice and Vα24Jα18 in humans, which is associated with Vβ chains of limited diversity [3] [4] [5] [6] , and are referred to as canonical or invariant NKT (iNKT) cells. Similar to conventional T cells, NKT cells develop from CD4-CD8-thymic precursor T cells following the appropriate signaling by CD1d
. The potential to utilize NKT cells for therapeutic purposes has significantly increased with the ability to stimulate and expand human NKT cells with α-Galactosylceramide (α-GalCer) and a variety of cytokines 8 . Importantly, these cells retained their original phenotype, secreted cytokines, and displayed cytotoxic function against tumor cell lines. Thus, ex vivo expanded NKT cells remain functional and can be used for adoptive immunotherapy. However, NKT cell based-immunotherapy has been limited by the use of autologous antigen presenting cells and the quantity and quality of these stimulator cells can vary substantially. Monocyte-derived DC from cancer patients have been reported to express reduced levels of costimulatory molecules and produce less inflammatory cytokines 9, 10 . In fact, murine DC rather than autologous APC have been used to test the function of NKT cells from CML patients 11 . However, this system can only be used for in vitro testing since NKT cells cannot be expanded by murine DC and then used for adoptive immunotherapy. Thus, a standardized system that relies on artificial Antigen Presenting Cells (aAPC) could produce the stimulating effects of DC without the pitfalls of allo-or xenogeneic cells 12, 13 . Herein, we describe a method for generating CD1d-based aAPC. Since the engagement of the T cell receptor (TCR) by CD1d-antigen complexes is a fundamental requirement of NKT cell activation, antigen: CD1d-Ig complexes provide a reliable method to isolate, activate, and expand effector NKT cell populations.
Video Link

Isolation of CD161 +
CD3
+ Cells
Collect peripheral blood mononuclear cells (PBMC)
. For Ficoll density gradient centrifugation separation of lymphocytes from a buffy coat or leukopheresis pack, first dilute heparinized blood with an equal volume of 1X PBS at room temperature. 2. Add 15 ml of Ficoll (warmed to room temperature) to 50 ml conical tubes. Slowly overlay 25 ml of the diluted blood mixture on top of the Ficoll. Centrifuge at 2,000 rpm for 30 min at room temperature with the brake off. 3. Carefully remove the lymphocyte interface (white ring between the media and Ficoll) with a Pasteur pipette and transfer to a new 50 ml conical tube. 4. Wash the cells by filling up the tube to 50 ml with PBS and centrifuging at 1,500 rpm for 5 min. Discard the supernatant and combine the tubes from a single individual to a single tube and wash the peripheral blood mononuclear cells (PBMC) again with 20 ml PBS. Then count the PBMC and resuspend at a concentration of 5 x 10 7 cells/ml in MACS buffer (1 L PBS free of Ca 2+ and Mg
2+
, 5 g BSA, and 2 mmol EDTA). 5. In order to isolate the T cell fraction, start with 2 ml of PBMC (10 8 2. Harvest cell culture supernatant for ELISA after 24-48 hr.
Representative Results
Herein we describe a method for generating CD1d-Ig based aAPC, made by covalent coupling of CD1d-Ig and anti-CD28 mAb to magnetic beads to stimulate NKT cells as a standardized method for the propagation of NKT cells (Figure 1) .First, one must demonstrate that the CD1d-Ig fusion proteins are stably immobilized onto the surface of the magnetic beads. As shown in Figure 2A , CD1d-Ig and anti-CD28 antibodies were both expressed on the surface of the magnetic beads. To examine the stimulatory capacity of the aAPC, we co-cultured NKT cell hybridomas with aAPC overnight, harvested the culture supernatants and measured IL-2 production by ELISA. We found that CD1d-Ig based aAPC were able to stimulate the NKT cell hybridomas at levels equal to or higher than their cellular counterparts (Figure 3 , data not shown). Interestingly, we found that our mouse NKT cell hybridomas are stimulated by human CD1d-based aAPC ( Figure 2B ), which provides simple method for testing each batch of aAPC.
Next, we sought to demonstrate the propagation potential of aAPC, thus human T cells were isolated from the peripheral blood. First the CD161 + CD3 + T cell fraction was enriched by magnetic bead separation. Then, the T cells were stimulated biweekly with α-GalCer-loaded aAPC.
Importantly, we found that even with a relatively low initial NKT cell population (0.03%), we were able to expand the cells to ~67% Vα24 
Discussion
aAPC can be used to study the basic requirements for NKT cell activation and it has potential clinical value for ex vivo expansion of NK T cells for adoptive immunotherapy. Mescher et al. described one of the first bead based systems, where biotinylated murine MHC class I-peptide-single chain constructs were combined with biotinylated costimulatory molecules B7.1 and B7.2 via streptavidin to the surface of latex microspheres 14, 15 . This approach has successfully been used to stimulate antigen-specific T cells from transgenic mice. In addition, since this approach uses a single chain MHC-peptide complex to ensure homogenous loading of the MHC molecules, each target peptide antigen would require a new transfection for expression of the desired single chain MHC-peptide complex, thus limiting the generality of the approach. Importantly, Dr. Schneck's group pioneered the bead based-aAPC, by developing another non-cellular bead based aAPC, made by coupling HLA-Ig, signal 1, and anti-CD28, signal 2, onto magnetic beads. HLA-Ig, a unique multimeric form of HLA fused to an immunoglobulin molecular scaffold 16, 17 was developed by his group. Subsequently, they developed MHC-Ig based aAPC, which have been shown to effectively expand CMV and MART-1 specific CTL 18 . Here, we have demonstrated that CD1d-Ig based aAPC can be used to expand functional NKT cells. One study has used a similar system to examine the physical interaction of NK cells with CD1d 19 . Notably, we have designed an artificial antigen presenting cell which is adaptable to any requirements we find necessary for optimal NKT cell proliferation. The aAPC expansion method provides a simple and reliable method for expanding and enriching human NKT cells. Our aAPC can be modified to systematically evaluate the role of a panel of potential costimulatory molecules and assess their role on NKT cell proliferation and function. Thus, aAPC represent a robust versatile technology useful for inducing and expanding NKT cells. The generation of aAPCs takes less than one week and is suitable for the production of large quantities of beads. However, a critical step in generating the aAPC is to confirm that CD1d-Ig is stably immobilized on the surface of the beads and to assess their functionality to ensure consistency from batch to batch. A potential limitation of the system is that there is not a mechanism in place to turn off stimulation, other than mechanical removal of the beads. Specifically, the engagement of the T cell receptor (TCR) with the antigen: CD1d/MHC complex typically generate the immunological synapse in concert with accessory/adhesion molecules, which can result in the induction of inhibitory or suppressive factors on both the T cell and antigen presenting cell. In the aAPC system, these factors may be upregulated by the T cell, but the bead will not express the cognate ligands for these receptors. . IL-33 is a specific ligand for ST2 and it has been shown that soluble ST2 can block IL-33 signaling. Thus, as an example of a future application, aAPC expressing ST2 could be generated and used to determine if one could selectively inhibit the production of Th2 cytokines while inducing Th1 cytokine secretion by NKT cells. It has also been reported that i.v. injection of Kb-expressing aAPC into C57BL/6 mice resulted in decreased lung metastasis of tumor 21 . Importantly, these data demonstrate that aAPC traffic to the lung and are able to activate effector T cell subsets. Therefore, one could generate multiple types of aAPC and examine the interplay between antigen specific T cell subsets. To summarize, these studies demonstrate that CD1d-Ig based aAPC can be used to replace normal cellular APC, and have to the potential to enhance current clinical approaches for NKT cell based-adoptive immunotherapy.
Disclosures
No conflicts of interest declared.
